Price (delayed)
$44.15
Market cap
$4.7B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.95
Enterprise value
$4.28B
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims
There are no recent dividends present for APLS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.